CoChat

The New Era of Drug Therapy for Obesity: The Evidence and the Expectations

Open access

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Abstract

There is an urgent need for effective pharmacological therapies to help tackle the growing obesity epidemic and the healthcare crisis it poses. The past 3 years have seen approval of a number of novel anti-obesity drugs. The majority of these influence hypothalamic appetite pathways via dopaminergic or serotoninergic signalling. Some are combination therapies, allowing lower doses to minimize the potential for off-target effects. An alternative approach is to mimic endogenous satiety signals using long-lasting forms of peripheral appetite-suppressing hormones. There is also considerable interest in targeting thermogenesis by brown adipose tissue to increase resting energy expenditure. Obesity pharmacotherapy has seen several false dawns, but improved understanding of the pathways regulating energy balance, and better-designed trials, give many greater confidence that recently approved agents will be both efficacious and safe. Nevertheless, a number of issues from preclinical and clinical development continue to attract debate, and additional large-scale trials are still required to address areas of uncertainty.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-015-0410-1

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Simplified schematic of hypothalamic energy regulatory pathways. Other pathways, including the reward circuitry, are involved in appetite and energy expenditure, but an understanding of the central role of the hypothalamus is useful in order to appreciate the mechanisms of action of several weight loss agents. AgRP agouti-related peptide, BAT brown adipose tissue, CART cocaine- and amphetamine-regulated transcript, GLP-1 glucagon-like peptide-1, NPY neuropeptide Y, POMC pro-opiomelanocortin, PYY peptide YY
Fig. 1 Simplified schematic of hypothalamic energy regulatory pathways. Other pathways, including the reward circuitry, are involved in appetite and energy expenditure, but an understanding of the central role of the hypothalamus is useful in order to appreciate the mechanisms of action of several weight loss agents. AgRP agouti-related peptide, BAT brown adipose tissue, CART cocaine- and amphetamine-regulated transcript, GLP-1 glucagon-like peptide-1, NPY neuropeptide Y, POMC pro-opiomelanocortin, PYY peptide YYCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 106 references

Cited by

See all 58

Metadata

Authors
Jones, B. J., & Bloom, S. R.
Affiliations
Hammersmith Hospital (GB)
Corresponding author
Bloom, Stephen R.
Venue
Drugs
Published
2015-05-19
Volume
75
Issue
9
Pages
935-945
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W2118611271
Cited by
58
References
106
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 12 · 2015: 2
FWCI
6.44
Type
journal article
Language
en
Open access
Locations
  • Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institute for Health and Care Research (FP7-HEALTH-2009-241592, FP7-HEALTH-2009-241592 EuroCHIP, NF-SI-0513-10080, NF-SI-0507-10337, ACF-2010-21-012, NF-SI-0513-10029)
  • Imperial College London
  • Directorate for Biological Sciences
  • Medical Research Council (FP7-HEALTH-2009-241592, MR/K02115X/1, MR/K023667/1, MR/L013088/1)
  • Biotechnology and Biological Sciences Research Council (BB/L004259/1, FP7-HEALTH-2009-241592 EuroCHIP, FP7-HEALTH-2009-241592)
  • NIHR Imperial Biomedical Research Centre
  • FP7 Health (2009-241592 EuroCHIP)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
anti-obesity drugs, obesity pharmacotherapy, appetite regulation, dopamine signaling, combination therapy, satiety hormones, brown adipose tissue, thermogenesis, resting energy expenditure, energy balance, drug approval, drug safety
MeSH terms
Energy Metabolism, Forecasting, Humans, Obesity, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. https://app.cochat.ai/papers/10.1007/s40265-015-0410-1
The paper
Jones, B. J., & Bloom, S. R. (2015). The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. Drugs. https://doi.org/10.1007/s40265-015-0410-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.